Biohaven Ltd. (NYSE:  BHVN) Securities Fraud Class Action

Biohaven Ltd. (NYSE: BHVN) Securities Fraud Class Action

Class Periodbetween March 24, 2023 and May 14, 2025
COMPANY       Biohaven Ltd. 
COURT United States District Court for the District of Connecticut
CASE NUMBER 3:25-cv-01120
JUDGE Honorable Janet C. Hall
CLASS PERIOD  March 24, 2023 through May 14, 2025
SECURITY TYPE  Securities

LEAD PLAINTIFF DEADLINE IS SEPTEMBER 12, 2025.

If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at [email protected].

Case Background:
A class action lawsuit was filed on behalf of those who purchased or otherwise acquired Biohaven Ltd. (“Biohaven”) (NYSE:  BHVN) securities between March 24, 2023, and May 14, 2025, inclusive (the “Class Period”).

Biohaven is a pharmaceutical company that develops and commercializes therapies for oncology, immunology, and neuroscience. Biohaven’s  product candidate drug, troriluzole, is used for the treatment of patients with spinocerebellar ataxia (“SCA”).  In May 2022, Biohaven announced that troriluzole failed to reach its primary endpoint in its Phase 3 Trial evaluating its efficacy and safety.  

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects.  Specifically, Defendants misrepresented and/or failed to disclose that: (1)  Biohaven overstated the sufficiency of the data in support of troriluzole and troriluzole’ s regulatory prospects as an SCA treatment; (2) once the truth was revealed, Biohaven would likely see a significant negative impact on its financial and business condition; and (3) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
 

What is a Lead Plaintiff?

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case.  Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Complete this form with your transactions in Biohaven Ltd. securities between March 24, 2023 and May 14, 2025.

Click Here to Print PDF of this Form

    Submit Your Information
    SUBMIT YOUR INFORMATION
    * Denotes required field
    Phone Country code
    Purchase Information
    Sales Information
    Did you purchase shares of Biohaven Ltd. prior to the Class Period?
    Are you a current or former employee of Biohaven Ltd.?
    The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. READ MORE
    I agree to the KTMC disclaimer
    I would like to receive new case alerts by email
    Scroll to Top